Volume | 25,151 |
|
|||||
News | - | ||||||
Day High | 0.59 | Low High |
|||||
Day Low | 0.55 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Bluejay Diagnostics Inc | BJDX | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
0.55 | 0.55 | 0.59 | 0.55 | 0.5533 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
153 | 25,151 | $ 0.5646615 | $ 14,202 | - | 0.4703 - 13.9799 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
16:07:45 | 2 | $ 0.555 | USD |
Bluejay Diagnostics Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
681.53k | 1.24M | - | 249k | -9.3M | -7.50 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Bluejay Diagnostics News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical BJDX Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 0.66 | 0.6999 | 0.4703 | 0.5609705 | 24,871 | -0.11 | -16.67% |
1 Month | 0.8351 | 0.8358 | 0.4703 | 0.6837026 | 26,597 | -0.2851 | -34.14% |
3 Months | 0.755 | 0.9668 | 0.4703 | 0.7914627 | 40,052 | -0.205 | -27.15% |
6 Months | 3.93 | 4.87 | 0.4703 | 1.30 | 43,850 | -3.38 | -86.01% |
1 Year | 6.802 | 13.9799 | 0.4703 | 5.62 | 685,877 | -6.25 | -91.91% |
3 Years | 109.40 | 125.00 | 0.4703 | 27.44 | 660,636 | -108.85 | -99.50% |
5 Years | 109.40 | 125.00 | 0.4703 | 27.44 | 660,636 | -108.85 | -99.50% |
Bluejay Diagnostics Description
Bluejay Diagnostics Inc develops, manufactures and markets innovative clinical diagnostic products that improve the quality of medical diagnoses by developing Point-of-Care tests that provide convenience, timeliness, compliance and low cost to physicians and patients in areas where timeliness of the initial triage assessment has a high impact on course of treatment. |